## 3 Results
\begin{table}
\begin{tabular}{c c c c} \hline
**Ocular Parameter** & **Not oGVHD** & **oGVHD** & \(p\) \\ \hline OSDI score & 12.0 (0–58.0) & 17.0 (0–50.0) & 0.3 \\  & [8.0–17.0] & [9.3–20.6] & \\ \hline Schirmer test (mm length 5\({}^{\prime}\)) & 20.0 (3.0–40.0) & 18.0 (2.0–40.0) & 0.3 \\  & [19.1–30.0] & [15.0–24.6] & \\ \hline TBUT (seconds) & 7.5 (2.0–15.0) & 7.0 (1.0–15.00) & 0.4 \\  & [6.1–8.2] & [6.0–8.2] & \\ \hline NEI score corneal staining & 1.0 (0–10.0) & 1.5 (0–12.0) & 0.4 \\  & [1.0–2.0] & [1.2–3.1] & \\ \hline \end{tabular}
\end{table} 
Table 2: Summary of ocular parameters analyzed in patients with or without oGVHD post-hemopoietic stem cell transplant (HSCT). Data are expressed as median (min-max) [95% CI]. OSDI = Ocular Surface Disease Index; NEI = National Eye Institute. \begin{table}
\begin{tabular}{c c c c} \hline
**Protein Name** & **Pre-HSCT (\(\mu\)g/\(\mu\)L)** & **Post-HSCT (\(\mu\)g/\(\mu\)L)** & \(p\) \\ \hline Total protein (TP) & 7.4 (2.7–16.6) & 5.5 (1.3–11.2) & \textless{}0.0001 \\  & [6.7–8.1] & [4.9–5.8] & \\ \hline Albumin (ALB) & 0.9 (0.1–2.6) & 1.1 (0.1–3.1) & 0.5 \\  & [0.7–1.1] & [0.9–1.5] & \\ \hline Lysozyme-C (LYS-C) & 2.2 (0.5–5.7) & 1.8 (0.3–4.5) & \textless{}0.001 \\  & [2.0–2.4] & [1.6–2.0] & \\ \hline Lactoferrin (LACTO) & 1.6 (0.1–4.0) & 1.2 (0.1–2.9) & \textless{}0.0001 \\  & [1.4–2.0] & [1.1–1.4] & \\ \hline Lipocalin-1 (LIPOC-1) & 1.6 (0.5–3.0) & 1.3 (0.4–2.5) & 0.05 \\  & [1.5–1.7] & [1.1–1.6] & \\ \hline Transferrin (TRANSF) & 0.2 (0.1–1.4) & 0.5 (0.1–1.4) & \textless{}0.0001 \\  & [0.2–0.2] & [0.4–0.5] & \\ \hline Zinc-alpha-2-glycoprotein & 0.4 (0.1–1.1) & 0.2 (0.1–0.7) & \textless{}0.0001 \\  (ZAG-2) & [0.3–0.5] & [0.1–0.2] & \\ \hline \end{tabular}
\end{table} 
Table 3: Levels of tear proteins analyzed in patients pre- and post-hemopoietic stem cell transplant (HSCT). Data are expressed as median (min-max) [95% CI]. Figure 2 summarizes the receiver operating characteristic (ROC) curve analyses performed for \(\Delta\) pre-post-TP, LACTO, TRANSF, ZAG-2. The area under the curve (AUC) \begin{table}
\begin{tabular}{c c c c c c c} \hline \hline  & \multicolumn{3}{c}{**No oGVHD**} & \multicolumn{3}{c}{**oGVHD**} \\ \hline
**Tear Protein** & \begin{tabular}{c} **Pre-HST** \\ **(ug/uL)** \\ \end{tabular} & \
\begin{tabular}{c} **Post-HST** \\ **(ug/uL)** \\ \end{tabular} & \(p\) &
\begin{tabular}{c} **Pre-HST** \\ **(ug/uL)** \\ \end{tabular} & \(\mathbf{Post-HST}\) & \(\mathbf{p}\) \\ \hline \multirow{2}{*}{TP} & 7.2 (2.7–14.5) & 5.8 (2.5–11.1) & \multirow{2}{*}{\(<\)0.001} & 7.4 (3.2–16.2) & 4.8 (1.3–11.2) & \multirow{2}{*}{\(<\)0.0001} \\  & [6.7–8.1] & [4.9–5.8] & & [6.8–8.6] & [3.8–5.7] & & \\ \hline \multirow{2}{*}{ALB} & 0.9 (0.1–2.6) & 1.3 (0.1–3.1) & \multirow{2}{*}{0.5} & 0.9 (0.1–2.5) & 1.1 (0.1–2.6) & \multirow{2}{*}{0.5} \\  & [0.7–1.1] & [0.8–1.5] & & [0.7–1.2] & [0.7–1.4] & & \\ \hline \multirow{2}{*}{LYS-C} & 2.2 (0.4–4.5) & 1.8 (0.7–4.5) & \multirow{2}{*}{\(<\)0.001} & 2.0 (1.2–5.7) & 1.8 (0.3–4.4) & \multirow{2}{*}{\(<\)0.1} \\  & [2.0–2.5] & [1.6–2.1] & & [1.8–2.4] & & \\ \hline \multirow{2}{*}{LACTO} & 1.1 (0.1–3.7) & 1.2 (0.4–2.8) & \multirow{2}{*}{\(<\)0.01} & 1.9 (0.4–4.0) & 1.2 (0.1–2.9) & \multirow{2}{*}{\(<\)0.0001} \\  & [1.2–1.8] & [1.1–1.4] & & [1.4–2.3] & & \\ \hline \multirow{2}{*}{LIPOC-1} & 1.5 (0.5–2.3) & 1.3 (0.3–2.5) & \multirow{2}{*}{0.07} & 1.6 (0.6–3.0) & 1.5 (0.5–2.1) & \multirow{2}{*}{0.1} \\  & [1.2–1.7] & [1.9–1.6] & & [1.5–1.8] & & \\ \hline \multirow{2}{*}{TRANSF} & 0.2 (0.1–0.5) & 0.4 (0.1–0.8) & \multirow{2}{*}{\(<\)0.0001} & 0.2 (0.1–1.4) & 0.7 (0.1–1.4) & \multirow{2}{*}{\(<\)0.001} \\  & [0.1–0.2] & [0.3–0.5] & & [0.2–0.2] & & \\ \hline \multirow{2}{*}{ZAG-2} & 0.4 (0.1–0.7) & 0.2 (0.1–0.7) & \multirow{2}{*}{\(<\)0.001} & 0.5 (0.1–1.1) & 0.2 (0.1–0.5) & \multirow{2}{*}{\(<\)0.001} \\  & [0.3–0.4] & [0.1–0.2] & & [0.5–0.6] & & \\ \hline \hline \end{tabular}
\end{table}